Iron Chelators in Treatment of Iron Overload

被引:68
|
作者
Entezari, Sarina [1 ]
Haghi, Seyedeh Mona [2 ]
Norouzkhani, Narges [3 ]
Sahebnazar, Barsa [4 ]
Vosoughian, Fatemeh [5 ]
Akbarzadeh, Diba [5 ]
Islampanah, Muhammad [6 ]
Naghsh, Navid [7 ]
Abbasalizadeh, Mohammad [8 ]
Deravi, Niloofar [5 ]
机构
[1] Shahid Beheshti Univ Med Sci, Student Res Comm, Sch Allied Med Sci, Tehran, Iran
[2] Mashhad Univ Med Sci, Student Res Comm, Sch Pharm, Mashhad, Iran
[3] Mashhad Univ Med Sci, Fac Med, Dept Med Informat, Mashhad, Iran
[4] Fasa Univ Med Sci, Student Res Comm, Fasa, Iran
[5] Shahid Beheshti Univ Med Sci, Student Res Comm, Sch Med, Tehran, Iran
[6] Mashhad Univ Med Sci, Fac Med, Mashhad, Iran
[7] Shahid Sadoughi Univ Med Sci, Dept Pharm, Yazd, Iran
[8] Tabriz Univ Med Sci, Fac Med, Tabriz, Iran
关键词
BETA-THALASSEMIA MAJOR; RANDOMIZED CONTROLLED-TRIAL; SICKLE-CELL-DISEASE; COMBINED ORAL CHELATION; LONG-TERM EFFICACY; QUALITY-OF-LIFE; PEDIATRIC-PATIENTS; MYELODYSPLASTIC SYNDROMES; COMBINED DEFERIPRONE; COMBINATION THERAPY;
D O I
10.1155/2022/4911205
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Patients suffering from iron overload can experience serious complications. In such patients, various organs, such as endocrine glands and liver, can be damaged. Although iron is a crucial element for life, iron overload can be potentially toxic for human cells due to its role in generating free radicals. In the past few decades, there has been a major improvement in the survival of patients who suffer from iron overload due to the application of iron chelation therapy in clinical practice. In clinical use, deferoxamine, deferiprone, and deferasirox are the three United States Food and Drug Administration-approved iron chelators. Each of these iron chelators is well known for the treatment of iron overload in various clinical conditions. Based on several up-to-date studies, this study explained iron overload and its clinical symptoms, introduced each of the above-mentioned iron chelators, and evaluated their advantages and disadvantages with an emphasis on combination therapy, which in recent studies seems a promising approach. In numerous clinical conditions, due to the lack of accurate indicators, choosing a standard approach for iron chelation therapy can be difficult; therefore, further studies on the issue are still required. This study aimed to introduce each of these iron chelators, combination therapy, usage doses, specific clinical applications, and their advantages, toxicity, and side effects.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] New aspects in the treatment with iron chelators
    Nolte, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 99 - 99
  • [32] Orally effective iron chelators for the treatment of iron overload disease: The case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs
    Richardson, DR
    Ponka, P
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (04): : 351 - 352
  • [33] Iron chelators and iron toxicity
    Brittenham, GM
    ALCOHOL, 2003, 30 (02) : 151 - 158
  • [34] Structure-activity relationships of novel iron Chelators for the treatment of iron overload disease: The methyl pyrazinylketone isonicotinoyl hydrazone series
    Kalinowski, Danuta S.
    Sharpe, Philip C.
    Bernhardt, Paul V.
    Richardson, Des R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (02) : 331 - 344
  • [35] THE ROLE OF IRON AND CHELATORS ON INFECTIONS IN IRON OVERLOAD AND NON IRON LOADED CONDITIONS: PROSPECTS FOR THE DESIGN OF NEW ANTIMICROBIAL THERAPIES
    Kontoghiorghes, George J.
    Kolnagou, Annita
    Skiada, Anna
    Petrikkos, George
    HEMOGLOBIN, 2010, 34 (03) : 227 - 239
  • [36] TREATMENT OF CHRONIC IRON OVERLOAD
    KIRKING, MH
    CLINICAL PHARMACY, 1991, 10 (10): : 775 - 783
  • [37] Diagnosis and treatment of iron overload
    Ruivard, Marc
    REVUE DE MEDECINE INTERNE, 2022, 43 : A304 - A307
  • [38] TREATMENT OF TRANSFUSIONAL IRON OVERLOAD
    COHEN, A
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1990, 12 (01): : 4 - 8
  • [39] Diagnosis and treatment of iron overload
    Ruivard, M.
    Lobbes, H.
    REVUE DE MEDECINE INTERNE, 2023, 44 (12): : 656 - 661
  • [40] Deferasirox.: Treatment of iron overload, iron chelator
    McIntyre, JA
    Castañer, J
    Mealy, NE
    Bayés, M
    DRUGS OF THE FUTURE, 2004, 29 (04) : 331 - 335